Alembic Pharmaceuticals Receives USFDA Approval for Methotrexate Injection

Alembic Pharmaceuticals announced it has received final approval from the USFDA for its Methotrexate Injection USP. The approval covers both multi-dose (50 mg/2 mL) and single-dose (1g/40 mL) vial formulations.

This medication is used to treat various cancers, including leukemia and breast cancer, and autoimmune conditions such as rheumatoid arthritis. The USFDA's final approval, dated April 16, 2026, adds to Alembic's growing portfolio of approved generics.

The company now holds a cumulative total of 236 Abbreviated New Drug Application (ANDA) approvals from the USFDA, with 218 final and 18 tentative approvals. This achievement highlights Alembic's success in developing and gaining regulatory approval for complex generic drugs.

Why It Matters

The USFDA approval for Methotrexate Injection USP marks an important expansion for Alembic Pharmaceuticals, providing market access for a key drug in the United States. This addition strengthens the company's oncology and autoimmune therapeutic areas and is expected to drive revenue growth in a major global pharmaceutical market.

The approval also reaffirms Alembic's reputation for regulatory compliance and its strong research and development capabilities in the generics sector. Successfully navigating the US FDA's strict regulatory process for this product is a key accomplishment.

Alembic's US Market Strategy

Alembic Pharmaceuticals has consistently built its US FDA approval pipeline, showing a clear strategy focused on the US market. The company regularly receives multiple ANDA approvals each year, including for complex injectables and cancer drugs. For example, it gained final approval for Doxorubicin Hydrochloride Liposome Injection in June 2025, following many other product approvals throughout 2024 and 2025, steadily growing its total ANDA count. Alembic's US subsidiary focuses on developing products specifically for the US market, using FDA-approved manufacturing facilities.

What Changes Now

• Market Access: Alembic can now market and sell Methotrexate Injection USP in the United States.
• Portfolio Boost: The drug strengthens Alembic's offerings in oncology and autoimmune disease treatments.
• Revenue Opportunity: The approval opens new avenues for revenue growth in the valuable US market.
• Regulatory Standing: It further solidifies Alembic's positive track record with the USFDA.

Risks to Watch

While this specific filing doesn't detail risks for the new injection, Alembic has encountered regulatory challenges previously. Its manufacturing facilities have received USFDA Form 483 observations for procedural issues at its Gujarat-based plants, including in November 2024 and February 2026. The company also recalled telmisartan tablets in March 2021 due to a labeling error. Maintaining strict adherence to changing regulatory standards and effectively managing any compliance observations will be vital for ongoing success.

Peer Comparison

Alembic competes in a dynamic generics market against global rivals such as Sun Pharma, Dr. Reddy's Laboratories, Teva Pharmaceuticals, and Fresenius Kabi. Many of these companies also maintain strong portfolios of generic injectables and oncology drugs. Teva Pharmaceuticals, for instance, offers its own FDA-approved generic Methotrexate Injection USP, indicating the competitive environment Alembic is entering with this approval.

What to Track Next

• The official US launch date and strategy for Methotrexate Injection USP.
• Sales figures and market share for the new product.
• Alembic's future ANDA filings and approvals from global regulators.
• The company's ongoing work to address USFDA observations and maintain compliance.